Development
Taysha Gene Therapies, Inc.
TSHA
$2.84
-$0.04-1.39%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 4.75M | 2.40M | 4.71M | 2.50M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.75M | 2.40M | 4.71M | 2.50M | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 4.75M | 2.40M | 4.71M | 2.50M | -- |
| SG&A Expenses | 8.59M | 5.99M | 8.75M | 6.64M | 8.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.38M | 25.78M | 21.27M | 19.80M | 25.46M |
| Operating Income | -15.63M | -23.38M | -16.56M | -17.30M | -25.46M |
| Income Before Tax | -117.09M | -24.60M | -17.62M | -55.72M | -26.53M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -117.09M | -24.60M | -17.62M | -55.72M | -26.53M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -117.09M | -24.60M | -17.62M | -55.72M | -26.53M |
| EBIT | -15.63M | -23.38M | -16.56M | -17.30M | -25.46M |
| EBITDA | -15.30M | -23.04M | -16.23M | -16.94M | -25.18M |
| EPS Basic | -0.93 | -0.38 | -0.28 | -0.99 | -0.65 |
| Normalized Basic EPS | -0.58 | -0.24 | -0.17 | -0.20 | -0.41 |
| EPS Diluted | -0.93 | -0.38 | -0.28 | -0.99 | -0.65 |
| Normalized Diluted EPS | -0.58 | -0.24 | -0.17 | -0.20 | -0.41 |
| Average Basic Shares Outstanding | 125.70M | 64.24M | 63.26M | 56.39M | 40.94M |
| Average Diluted Shares Outstanding | 125.70M | 64.24M | 63.26M | 56.39M | 40.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |